⚕ GalenOps field
←

SITE013-0056

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-04-24

AEs
6
Serious
2
Dropout signal
–

Adverse events

severe serious assessed

Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-06-21 (study day 40); relationship: N; serious criteria: hospitalization

severe assessed

Grade 3 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-07-06 (study day 55); relationship: not assessed

mild assessed

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-10-15 (study day 156); relationship: not assessed

severe serious assessed

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-15 (study day 217); relationship: N; serious criteria: hospitalization

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-29 (study day 231); relationship: not assessed

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-25 (study day 258); relationship: not assessed

Data queries

No data queries.